Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is safe and effective in moderate-to-severe plaque psoriasis, providing a persistent and long-term clinical response through 108 weeks of treatment, reports a recent study.
It appears that nearly every resident in institutional long-term care is affected by at least one dermatological condition, with dermatological findings ranging from highly prevalent xerosis and cutaneous infection to skin cancer, according to a study.
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
Poor sleep quality is not uncommon among patients with psoriatic disease, suggests a recent study. Poor sleep is associated with fatigue, anxiety and lower EQ-5D. It is also associated with actively inflamed joints in patients with psoriatic arthritis (PsA).
Acne is a ‘pain,’ as many will attest. It may not be life-threatening, but its impact on quality of life can be great. For the many people who have had to put up with it for a long time, there is frustration and embarrassment, and even anger and depression. Nevertheless, there is hope.